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Abstract
One principal process driving fatty acid transport is vectorial acylation, where fatty acids traverse 
the membrane concomitant with activation to CoA thioesters. Current evidence is consistent with 
the proposal that specific fatty acid transport (FATP) isoforms alone or in concert with specific 
long chain acyl CoA synthetase (Acsl) isoforms function to drive this energy-dependent process. 
Understanding the details of vectorial acylation is of particular importance as disturbances in lipid 
metabolism many times leads to elevated levels of circulating free fatty acids, which in turn 
increases fatty acid internalization and ectopic accumulation of triglycerides. This is associated 
with changes in fatty acid oxidation rates, accumulation of reactive oxygen species, the synthesis 
of ceramide and ER stress. The correlation between chronically elevated plasma free fatty acids 
and triglycerides with the development of obesity, insulin resistance and cardiovascular disease 
has led to the hypothesis that decreases in pancreatic insulin production, cardiac failure, 
arrhythmias, and hypertrophy are due to aberrant accumulation of lipids in these tissues. To this 
end, a detailed understanding of how fatty acids traverse the plasma membrane, become activated 
and trafficked into downstream metabolic pools and the precise roles provided by the different 
FATP and Acsl isoforms are especially important questions. We review our current understanding 
of vectorial acylation and the contributions by specific FATP and Acsl isoforms and the 
identification of small molecule inhibitors from high throughput screens that inhibit this process 
and thus provide new insights into the underlying mechanistic basis of this process.
INTRODUCTION
Fatty acids are enigmatic molecules that on the one hand are essential for cellular structure, 
function and signaling and on the other must be contained or their detergent properties will 
prove lethal to cells. Mother nature has therefore developed ways to compartmentalize, 
sequester and regulate the movement of these molecules between and within cells. Within 
the blood stream free fatty acids (FFA) are buffered and moved by serum albumin and, as 
complex lipids, by the lipoproteins. Within cells, the fatty acid binding proteins serve a 
similar function for the free carboxylic acids (see review by Newberry and Davidson within 
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this issue), while fatty acids esterified in highly hydrophobic complex lipid species are 
partitioned into membranes or sequestered in lipid droplets.
Understanding how free fatty acids move across membrane barriers has proven to be a 
challenging biophysical and biochemical problem, which after 30 years of research is still 
only poorly understood and remains somewhat controversial. Within the present article, we 
will review the arguments for protein mediated transport and will make the case that some 
members of the FATP family serve this function. The hypothesis that FATPs function in the 
transport of long chain fatty acids into cells was based on their identification though 
functional cloning of the first family member and has been supported by molecular and 
biochemical studies from our lab using a yeast model system, as well as studies using more 
complex animal cell and gene knockout approaches. However, the main hypothesis remains 
unproven, in part, because these proteins also function in the activation of certain lipophilic 
molecules by catalyzing the thioesterification of these substrates with coenzyme A. Thus, 
we will discuss the roles of these proteins in transport, activation and further metabolism of 
fatty acids.
FATTY ACID TRANSPORT IN HISTORICAL PERSPECTIVE
Upon presentation to the cell, fatty acids must be transported across the cell membrane and 
trafficked to sites of utilization. The free fatty acid concentration in the extracellular space is 
generally extremely low. Therefore the efficient transport of long-chain fatty acids is 
expected to require specific membrane-bound and membrane-associated transport systems to 
accumulate these compounds against a concentration gradient. Many different cell types 
contain a specific repertoire of membrane-bound and membrane-associated proteins, which 
are hypothesized to govern fatty acid transport in response to differentiation, hormonal 
stimulus, or environmental stimulus, including changes in nutritional state, temperature, or 
oxygen availability (1-6)).
The kinetics governing the transport of fatty acids into the cell is consistent with a protein-
mediated process (7-13). In studies using model membranes, it has been demonstrated that 
uncharged fatty acids can flip between the two faces of the membrane, but remain 
membrane-bound (14). More recent studies have shown that as the radius of membrane 
curvature increases the flip of fatty acids between the two membrane faces becomes rate 
limiting (15). For fatty acids in the uncharged form, the flip of fatty acids between the two 
membrane leaflets in small unilammellar vesicles is very fast (t1/2 msec to sec). On the other 
hand, this step is slow for fatty acid anions (t1/2>2sec) (14). The movement of fatty acids out 
of the membrane is very slow unless there are specific enzymes or binding proteins, which 
in turn function to target the fatty acid into downstream metabolism and intracellular 
signaling. We hypothesize there is a cooperative interaction between factors involved in 
transmembrane movement and those involved in intracellular movement (e.g. FABP, Acsl, 
ACBP) that function to target the imported fatty acids to specific subcellular locations and 
metabolic fates. Based on our current understanding, proteins are likely to be involved in at 
least three aspects of this process: delivery of fatty acids to the membrane; in the 
transmembrane movement of the fatty acid from one leaflet to the other (particularly for 
fatty acid anions); and in the removal of fatty acids from the membrane.
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Specific membrane-bound and membrane-associated proteins have been identified that 
appear to function in one or more of the steps detailed above in the transport of fatty acids 
across the membrane. To date, four different membrane-bound or membrane associated 
proteins have been defined in eukaryotic cells that participate in the transport of exogenous 
long-chain fatty acids: CD36/fatty acid translocase (CD36/FAT; see article by Nassir and 
Abumrad in this series) (1), fatty acid binding protein – plasma membrane-bound 
(FABPpm) (16), fatty acid transport protein (FATP) (17, 18), and long chain acyl CoA 
synthetase (Acsl) (2, 19). The roles of FAT/CD36 and FABPpm have been recently 
reviewed by others and will not be detailed further herein (6, 20, 21); rather this review will 
focus on the FATP isoforms with some discussion on their association with different Acsl 
isoforms.
FATP, FATTY ACID TRANSPORT PROTEIN OR ACYL-COA SYNTHETASE?
Fatty acid transport protein (FATP1) was first identified in a functional cloning screen 
designed to identify proteins that resulted in elevated accumulation of the fluorescent fatty 
acid analogue C1-BODIPY-C12 (12). It was immediately recognized that FATP has a 
domain architecture similar to the acyl-CoA synthetases, which includes an ATP binding 
domain and a fatty acid binding domain (12, 22, 23). Thus began the controversy over 
whether or not FATP was a bona fide transporter or merely functioned in vectorial acylation 
as a fatty acid activating enzyme trapping fatty acid within the cell through metabolic 
utilization. Our lab exploited the molecular genetics of Saccharomyces cerevisiae to 
distinguish the functions of this protein in transport and activation (22, 24). Several clues 
indicated that the two functions might be separable. First, the fatty acid signature of the 
FATPs was divergent from the Acsl enzymes involved in activation of long chain fatty acids 
(24, 25). Indeed, several labs demonstrated that in yeast, deletion of the FATP homologue 
Fat1p did not affect long chain Acsl activity, but reduced activation of very long chain fatty 
acids (26, 27). These strains also accumulated very long chain fatty acids suggesting 
turnover of fatty acids >C20 in length was reduced. Deletion of the same gene rendered 
yeast strains unable to transport long chain fatty acids into the cells (22). Yeast do not 
import very long chain fatty acids so that function could not be tested. We further 
demonstrated through an extensive site-directed mutagenesis approach that variants could be 
identified that either affected activation or transport, separating the two functions (24).
In addition to the first FATP, five other related mammalian genes (called FATP2 through 
FATP6) have been cloned and their proteins characterized. The FATPs differ in expression 
pattern, tissue distribution and subcellular location. FATP1 is found in muscle and adipose 
tissue; FATP2 in liver and kidney; FATP3 in liver and testes; FATP4 is relatively ubiquitous 
in fat metabolizing tissues and skin; FATP5 is exclusive to liver; and FATP6 is exclusive to 
heart (28, 29). Depending on the specific FATP, each protein functions in thioesterification 
of a lipophilic substrate with coenzyme A. FATP1, FATP2 and FATP4 have both Acsvl 
activity and transport long chain fatty acids when examined in yeast and several mammalian 
cells lines (11, 22, 24). FATP 5 is a bile-CoA ligase (30, 31). FATP6 in yeast activates very 
long chain fatty acids but does not transport fatty acids of any chain length (32). In contrast, 
the sole activity assigned this protein in heart cells, where it was first identified, is fatty acid 
transport (33). Figure 1 illustrates an overview of how the FATPs are likely to function, 
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alone or in concert with a long chain acyl CoA synthetase (Acsl) in fatty acid transport and 
activation. Studies that are presently underway are directed to address specificity, 
compartmentalization and selectivity in directing intracellular fatty acid trafficking. As 
detailed blow, targeted deletions in several of the FATP genes are consistent with roles in 
fatty acid transport and/or intracellular fatty acid trafficking.
TARGETED DELETIONS OF FATP GENES PROVIDE FEW CLUES AND 
MANY QUESTIONS REGARDING FUNCTION
Germline deletions in mice have been constructed for FATP1, FATP2, FATP4 and FATP5. 
Each, except the FATP4 deletion, was viable. Deletion of FATP1 did not alter fat 
metabolism or insulin sensitivity when the knockout mice were fed a standard chow diet 
(34). However, on a high fat diet the mice were protected from fat-induced insulin resistance 
and intramuscular accumulation of fatty acyl-CoA. Overexpression of FATP1 specifically in 
heart, resulted in lipotoxicity and cardiomyopathy without systemic disturbances in lipid 
metabolism or disturbances in insulin sensitivity (35). The cardiac dysfunction was 
attributed to excessive accumulation of lipids due to increased uptake and metabolism.
A deletion of FATP2/ACSVL1 in mice was engineered to specifically examine the effects of 
this protein in very long chain fatty acid metabolism since it was first identified as an Ascvl 
enzyme (36). It was hypothesized this protein was the peroxisomal Ascvl involved in the 
accumulation of very long chain fatty acids that are characteristic in patients affected with 
adrenoleukodystrophy. The FATP2 knockout mice were viable and had no obvious systemic 
or metabolic abnormalities apart from reduced peroxisomal Ascvl activity and VLCFA beta-
oxidation. However, the knockout mice did not accumulate very long chain fatty acids or 
develop symptoms characteristic of adrenoleukodystrophy. Fatty acid uptake was not 
examined in tissues from these animals.
FATP4 knockouts cause neonatal lethality that was attributed to a restrictive dermopathy 
that prevented expansion of the diaphragm and the pups died within hours of birth by 
asphyxiation (37, 38). The epidermal ceramides had altered fatty acid composition with a 
decrease in the C26:0 and C26:0-OH fatty acid side chains, which was considered a major 
cause of the epidermal malfunction (38). Davidson and coworkers recently rescued the skin 
phenotype and embryonic lethality using an FATP4 transgene driven by a keratinocyte-
specific promoter to evaluate the role of intestinal FATP4 in dietary lipid absorption (39). 
The growth and maturation of the mice was normal and they were examined for intestinal 
lipid absorption as adults. Fatp4−/−;Ivl-Fatp4tg/+ mice and wild type littermates displayed 
indistinguishable food consumption, growth and weight gain on either a low fat chow or 
high fat Western diet. There were no differences in intestinal triglyceride (TG) absorption or 
fecal fat loss, indicating loss of FATP4 did not reduce fatty acid uptake or metabolism 
across the GI track. Similarly, compounds identified as FATP4-specific inhibitors using a 
high throughput screening method did not reduce GI-specific fatty acid absorption in rodents 
(40).
Expression of FATP5 is restricted to liver where it is involved in bile acid recycling and 
fatty acid uptake as evidenced by studies in isolated cells and in the tissues of genetically 
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ablated mice (4, 30, 31). FATP5 deletion significantly reduced LCFA uptake by hepatocytes 
isolated from FATP5 knockout animals. Livers of these mice had reduced triglycerides and 
free fatty acids concomitant with a redistribution of lipids to other LCFA-metabolizing 
tissues. In keeping with its function as a bile-CoA ligase, bile acid recycling was reduced in 
FATP5 knock out animals. Interestingly, FATP5 deletion mice failed to gain weight on a 
high-fat diet, had reduced food intake and increased metabolic rate. These varying 
phenotypes point to the complexity involved in dietary and endogenous lipid trafficking and 
metabolism.
Given the various tissue distributions it is not surprising that the different FATP deletion 
mice had unique and relatively non-overlapping phenotypes. As reviewed above, FATP4 is 
essential for functioning of skin, FATP5 for bile acid recycling, and FATP1 for fatty acid 
trafficking in adipose tissue and muscle. However, none of the FATP proteins (or any other 
putative fatty acid transporter, e.g. CD36, FABPpm) thus far has been demonstrated to be 
essential for lipid uptake in the GI track by studying mice with targeted deletions. (28, 29)
REGULATION OF FATP-DEPENDENT FATTY ACID TRANSPORT
The levels of long-chain fatty acids in blood decrease in response to insulin, but it is unclear 
if this is due to a combination of decreased release and increased uptake (41). Insulin 
induces adipocyte differentiation (42) and during that process FATP1 and Acsl1 are strongly 
induced (11, 41). The increased expression of these proteins correlates with an increase in 
fatty acid uptake under the same conditions (11, 43, 44). On the other hand, in mature 
adipocytes insulin acts as a negative regulator of FATP1 expression (45) and as a positive 
regulator of Acsl1 expression (46). Yet insulin treatment has been reported to promote the 
translocation of FATP1 to the plasma membrane where it facilitates fatty acid uptake (41). 
Murine FATP1 mRNA levels are also increased during starvation, which correlates with low 
levels of insulin (45). This contrasting information seems to indicate that insulin potentiates 
FATP1 protein function while, at the same time, depresses FATP1 gene expression.
FATP1 has been linked directly to human dyslipidemia. A Swedish study examined FATP1 
variants in over 1,000 healthy men and women (47). It was reported that a G/A substitution 
at position 48 in intron 8 of FATP1 was associated with increased postprandial lipemia, 
including elevated triglycerides, and smaller LDL particles in homozygous A/A individuals. 
These findings suggest that through regulation of non-esterified fatty acid trafficking FATP1 
is involved in postprandial lipid metabolism and development of cardiovascular disease.
As with many fatty acid metabolic genes, expression of the FATP genes is controlled, in 
part, by PPAR transcription factor family members. In liver, treatment with a PPARα 
agonist induced the expression of a number of genes involved in fatty acid import, among 
them FATP1 (48, 49). PPARδ has been showed to induce lipid uptake and/or accumulation 
in adipose tissue, muscle, liver, macrophages and placental trophoblasts (50). Activation of 
PPARδ promotes adipocyte terminal differentiation, which correlates with an increase in 
FATP1 expression (48, 49, 51). In human placental trophoblast cells, PPARδ enhances fatty 
acid uptake and accumulation, and also increases the expression of FATP1 and FATP4 (52). 
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Treatment of pregnant mice with a PPARδ agonist alters placental morphology and induces 
FATP1 and −4 expression while decreasing expression of FATP-2, -3, and -6 (53).
THE SEARCH FOR SMALL COMPOUND INHIBITORS
To further understand the roles of the FATP proteins in fatty acid uptake and intracellular 
trafficking, we devised a screening method for small compound inhibitors (P. N. Black and 
C. C. DiRusso, United States Patent 7,070,944) (9, 10). In designing this system we took 
advantage of a yeast strain that is deficient in fatty acid transport (Δfat1) and has reduced 
long chain acyl-CoA synthetase activity (Δfaa1). The strain was transformed with a plasmid 
encoding human FATP2, the intended target of the inhibitor screening. Using this procedure, 
a 2,080 compound library, SpectrumPlus (MicroSource), was screened to identify 
compounds that reduced the uptake of the fluorescent fatty acid analog 4,4-difluoro-5-
methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C1-BODIPY-C12). Primary and 
secondary screens were performed to eliminate false positives and a total of 28 compounds 
were selected as potential inhibitors of human FATP2-mediated fatty acid uptake (9). These 
compounds were further evaluated for specificity and efficacy in human intestine-derived 
Caco-2 cell line. Caco-2 cells express FATP2 and FATP4 and efficiently import fatty acids 
and incorporate them into higher lipids (11). Subsequently, these potential inhibitors were 
sorted into different groups according to structural features. As expected, one group was 
similar to fatty acids in having a long hydrocarbon chain. Two other groups were of 
particular interest because they included drugs used to treat schizophenia but that are also 
known to cause obesity, hypertriglycerdemia and type II diabetes (54-59). These included 
dibenazepines and phenothiazines such as clozapine and chlorpromazine, respectively.
The connection between antipsychotic medications and their unwanted metabolic side 
effects has been widely reported (reviewed in (58)), however the mechanism responsible for 
this close association has not been elucidated. Different mechanisms have been proposed 
including: binding of these drugs to serotonin, norepinephrine, dopamine, histamine and 
serotonin receptors; disruption of the hypothalamic regulation of glucose serum levels 
through hypothalamic dopamine antagonism; and unspecified direct effects on glucose 
metabolism. However, our identification of some of these drugs as fatty acid uptake 
inhibitors may indicate a more direct effect on fatty acid and complex lipid metabolism.
The correlations between antipsychotics and metabolic disorders vary, with the highest risks 
reported for chlorpromazine, clozapine and olanzapine (58-60). The association of the 
chronic use of the atypical antipsychotics with new-onset hyperlipidemia in adults with 
psychotic disorders has been established by considering the odds ratio between treated and 
untreated individuals as reference (61). The highest values correspond to clozapine at 1.82 
(95% confidence limit (CL) 1.61–2.05) and olanzapine at 1.56 (CL, 1.47–1.67). Patients 
treated with either of these compounds had noticeable increases in weight and adiposity with 
both short- and long-term treatment. Several studies developed using a variety of 
methodologies support these observations (58). A mean increase of 4.45 kg with clozapine 
treatment and 4.15 kg with olanzapine treatment has been reported for a 10-week 
comparison study (62); longer-term treatment with clozapine was associated with additional 
weight increases up to 7.5 kg reached over a mean duration of 25 weeks (63).
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The effect of these antipsychotic agents on serum lipid levels has also been examined. 
Statistically significant increases in mean plasma triglyceride levels from baseline were 
observed in diverse clinical studies with the most significant changes correlating with 
olanzapine and chlozapine (57, 58). On the other hand, perphenazine treatment was not 
associated with an increase in serum triglycerides and in at least one study, a significant 
decrease was recorded (64). The effects of clozapine treatment on total cholesterol levels are 
less clear and more difficult to interpret since there are discrepancies in studies reporting 
both statistically and non-statistically significant variations in cholesterol levels from 
baseline (65-68). In follow-up studies to our HTS screening trials we found that 
perphenazine, chlorpromazine and clozapine inhibited the uptake of the fluorescent fatty 
acid analog C1-BODIPY-C12 in Caco-2 cells with Kis in the high micromolar range (Table 
1).
So the question becomes, is there a direct correlation between fatty acid uptake inhibition 
and the drug induced metabolic side effects including hypertriglyceridemia and obesity? 
This is a difficult question to answer with the limited information at hand. Our studies were 
done using an immortalized human intestinal cell line while the clinical studies report effects 
on whole body metabolism. We do know that there is not a direct correlation between Ki of 
uptake inhibition and relative severity of obesity and hypertriglyceridemia. For example, 
while we targeted perphenazine, chlozapine and chlorpromazine in humanized yeast, they 
were less effective in Caco-2 cells. We found the inhibition of transport was perphenazine> 
chlozapine or chlomipirmine while clinical studies did not demonstrate a correlation 
between perphenzine treatment and elevated serum triglycerides.
For the compounds that both inhibit fatty acid uptake in isolated cell systems and increase 
triglycerides in patients, we question why inhibition of fatty acid import would result in 
weight gain and obesity, processes that would require fatty acid accumulation in adipocytes. 
The answer might lie in the affinity and specificity of the drug for particular fatty acid 
transport proteins that govern fatty acid distribution between various tissues. If adipocytes, 
for example, were relatively insensitive to a specific compound then they might accumulate 
fat that is not being oxidized by muscle resulting in weight gain; while sensitivity of 
myocytes to fatty acid uptake inhibition by the same compounds might increase demand for 
glucose as an energy source by these cells, thus disrupting insulin regulation. Our 
investigations on both the FATP proteins and the inhibitory compounds are ongoing with the 
goal of providing a mechanistic understanding of these processes. We plan to define 
structure-activity relationships (SAR) between these compounds and the FATPs with the 
goal of generating rationally designed molecules that interact specifically with either 
neuroreceptors or a fatty acid transport protein. The results of these studies may lead to 
drugs useful to treat psychotic disorders without causing metabolic disorders as well as to 
other drugs useful to treat obesity-related disorders.
CONCLUSIONS
Members of the FATP family are multifunctional proteins that have overlapping as well as 
distinct functions in lipid metabolism. There is substantial evidence supporting a role for 
FATP1, FATP2 and FATP4 in both fatty acid transport and very long chain fatty acid 
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activation. It is unclear at present whether or not these proteins will be beneficial targets as 
pharmacological inhibitors. However, small compound inhibitors hold great promise as tools 
to uncover mechanisms of fatty acid transport and activation dependent upon these proteins. 
FATP5 is probably a minor player in fatty acid transport but plays a major role in bile acid 
recycling. Much work remains to be done on FATP3 and the cardiac-specific FATP6 to 
further define their roles in fatty acid metabolism.
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Figure 1. 
Overview of FATP and Acsl functions in fatty acid transport and intracellular trafficking. 
The movement of fatty acids (FFA) across the plasma membrane (PM) through vectorial 
acylation requires FATP alone or in combination with an Acsl; the resulting product is acyl 
CoA. FFA may also move across the membrane by a diffusion process that may involve 
intracellular fatty acid binding proteins. Prior to any type of metabolic transformation, this 
fatty acid must also be activated to form acyl CoA. As illustrated this may proceed in the 
endoplasmic reticulum (ER) through specific FATPs or Acsls individually or through an 
FATP/Acsl complex. As illustrated acyl CoA is the crucial intermediate that is required for 
b-oxidation and synthesis of complex lipids and triglycerides (TAG). As part of normal lipid 
turnover or lipolysis of TAG is the formation of FFA, which must be reactivated to enter the 
metabolic pools. Acyl CoA is shown as a single pool, but in all likelihood these pools are 
compartmentalized, for example as is the case for those involved in acyl chain modification 
(elongation and desaturation). The role of the different FATP and Acsl isoforms is thought 
to promote both specificity and selectivity to these processes.
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Table 1
IC50 values and 95% Confidence Intervals (95% CI) for C1-BODIPY-C12 uptake in the yeast strain expressing 
hsFATP2 (“humanized yeast”) and in Caco-2 cells.
Yeast expressing hsFATP2P Caco-2 cells
Perphenazine 23.4μM(95% CI, 19.5μM - 27.9μM)
79.0μM
(95% CI, 72.8-μM – 85.6μM)
Clozapine 98.8μM(95% CI, 70.4μM – 138.5μM)
537.1μM
(95% CI,174.8μM – 1652.2 μM)
Clomipramine 74.6μM(95% CI, 46.1μM – 120.8μM)
231.4μM
(95% CI, 212.4μM – 250.2μM)
Chlorpromazine 37.8μM(95% CI, 30.5μM – 46.9μM)
258.7μM
(95% CI, 194.3μM – 340.1μM)
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